SFA Therapeutics

Regulating the immune system to block cancer & autoimmune diseases

SFA Therapeutics operates in healthcare based in Philadelphia, PA, USA, founded in 2016.

Profile

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.

Within the healthcare space, the company focuses on its core offering rather than a broad product line.

The business is associated with Philadelphia, PA, USA.

The company is listed at the Summer 2021 stage of development.

Its team size is recorded as 4 employees.

It has disclosed roughly $8.7M in funding.

Website: sfatherapeutics.com